A new study is offering fresh insight into the effectiveness of respiratory syncytial virus (RSV) vaccines, particularly for older adults. While initial trials focused on preventing severe illness, researchers have uncovered a significant benefit: a reduction in hospitalizations due to RSV. This finding, published in the New England Journal of Medicine, builds upon earlier research demonstrating the vaccine’s efficacy and safety, and could reshape public health strategies for managing the common, yet potentially dangerous, virus.
RSV is a common respiratory virus that usually causes mild, cold-like symptoms. However, it can be severe in infants and older adults. Before the development of vaccines, RSV led to an estimated 60,000–160,000 hospitalizations each year among adults 65 years and older in the United States, according to the Centers for Disease Control and Prevention. The recent advancements in vaccine technology offer a promising new layer of protection for this vulnerable population.
The research centers around an mRNA-based RSV vaccine, known as mRNA-1345. A single dose of this vaccine has been shown to significantly lower the incidence of RSV-associated lower respiratory tract disease. Importantly, the study also revealed a substantial decrease in RSV-related hospitalizations, a key metric for assessing the vaccine’s real-world impact. This is particularly crucial as hospital systems continue to grapple with capacity challenges.
The vaccine utilizes a prefusion F protein, a stabilized form of a protein on the surface of the RSV virus. This approach aims to elicit a stronger and more broadly protective immune response. Recent data, published August 30, 2025, further supports the vaccine’s effectiveness in preventing hospitalization due to RSV as reported in the New England Journal of Medicine. The bivalent RSV prefusion F protein–based vaccine (RSVpreF) has shown promise in clinical trials.
The initial study, detailed in the New England Journal of Medicine, involved a large cohort of older adults. Participants receiving the mRNA-1345 vaccine experienced a notable reduction in RSV-associated lower respiratory tract disease compared to those who received a placebo. Crucially, the vaccine demonstrated a favorable safety profile, with no evident safety concerns identified during the trial period. This is a critical factor for widespread adoption, particularly among individuals with underlying health conditions.
How the Vaccine Works: A Closer Seem at the mRNA Technology
The mRNA technology used in the vaccine is the same platform that proved highly successful in the development of COVID-19 vaccines. This technology delivers genetic instructions to the body’s cells, prompting them to produce a harmless piece of the RSV virus – the prefusion F protein. This triggers an immune response, preparing the body to fight off the virus if exposed in the future. The mRNA itself does not integrate into the body’s DNA and is quickly broken down.
The advantage of using the prefusion F protein lies in its stability. Unlike other forms of the F protein, the prefusion form maintains its shape, allowing the immune system to recognize and neutralize the virus more effectively. This targeted approach enhances the vaccine’s potency and broadens its protective capabilities.
Beyond Prevention: The Implications for Public Health
The findings have significant implications for public health strategies aimed at mitigating the impact of RSV. Prior to the availability of vaccines, management of RSV primarily focused on supportive care, such as hydration and symptom relief. Now, with a preventative option available, healthcare providers can proactively protect vulnerable populations.
The reduction in hospitalizations observed in the study is particularly noteworthy. Hospitalizations not only represent a significant burden on healthcare systems but also carry risks for patients, including secondary infections and prolonged recovery times. By preventing hospitalizations, the RSV vaccine can improve patient outcomes and alleviate strain on healthcare resources.
The success of the mRNA-1345 vaccine and the RSVpreF vaccine also paves the way for the development of other mRNA-based vaccines targeting a wider range of respiratory viruses. This could lead to a more comprehensive approach to preventing and controlling infectious diseases.
Who Should Consider the RSV Vaccine?
Currently, the Centers for Disease Control and Prevention (CDC) recommends RSV vaccination for adults 60 years and older, based on shared clinical decision-making with their healthcare provider. The CDC also recommends RSV immunization for pregnant people during weeks 32 through 36 of pregnancy to protect their babies. Individuals with certain underlying health conditions, such as heart or lung disease, may benefit particularly from vaccination. Consulting with a healthcare provider is essential to determine individual suitability and timing for vaccination.
Looking ahead, researchers will continue to monitor the long-term effectiveness and safety of the RSV vaccines. Further studies will also explore the potential for combination vaccines that protect against multiple respiratory viruses, including RSV and influenza. The next key update regarding RSV vaccine recommendations is expected from the CDC’s Advisory Committee on Immunization Practices (ACIP) in the fall of 2026.
This research represents a significant step forward in the fight against RSV, offering a new tool to protect older adults and reduce the burden of this common, yet potentially serious, respiratory virus. Share your thoughts on this important development in the comments below.
